Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

[A case in which chromosome 5q deletion syndrome resistant to lenalidomide therapy transformed to refractory anemia with excess blasts].

Yamada M, Kuroda H, Jomen W, Yoshida M, Miura S, Abe T, Sakurai T, Fujii S, Maeda M, Fujita M, Nagashima K, Arihara Y, Hirako T, Kato J.

Gan To Kagaku Ryoho. 2013 Dec;40(13):2593-7. Japanese.

PMID:
24335378
2.

5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.

Ortega M, Mallo M, Solé F, Sánchez-Morata C, López-Andreoni L, Martínez-Morgado N, Gironella M, Valcárcel D, Vallespí T.

Leuk Res. 2013 Oct;37(10):1248-50. doi: 10.1016/j.leukres.2013.06.021. Epub 2013 Jul 26.

PMID:
23891188
3.

Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome.

Breccia M, Cannella L, Latagliata R, Loglisci G, Salaroli A, Santopietro M, Oliva EN, Alimena G.

J Clin Oncol. 2011 May 10;29(14):e402-3. doi: 10.1200/JCO.2010.33.5083. Epub 2011 Feb 28. No abstract available.

PMID:
21357784
4.

Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia.

Iizuka H, Yoshimi A, Yamamoto G, Masuda A, Nannya Y, Ichikawa M, Yatomi Y, Kurokawa M.

Rinsho Ketsueki. 2013 May;54(5):468-72. Japanese.

PMID:
23727686
5.

5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).

Ureshino H, Kizuka H, Kusaba K, Sano H, Nishioka A, Shindo T, Kubota Y, Ando T, Kojima K, Kimura S.

Int J Hematol. 2017 May;105(5):692-696. doi: 10.1007/s12185-016-2160-6. Epub 2016 Dec 2. Review.

PMID:
27914067
6.

A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.

Voutsadakis IA, Cairoli A.

Leuk Lymphoma. 2012 May;53(5):779-88. doi: 10.3109/10428194.2011.623255. Epub 2011 Nov 25. Review.

PMID:
21955212
7.

The role of lenalidomide in the management of myelodysplasia with del 5q.

Kelaidi C, Eclache V, Fenaux P.

Br J Haematol. 2008 Feb;140(3):267-78. doi: 10.1111/j.1365-2141.2007.06910.x. Review.

PMID:
18217896
8.

Tetraploidy and 5q deletion in myelodysplastic syndrome: a case report.

Znoyko I, Stuart RK, Ellingham T, Winters J, Wolff DJ, Quigley DI.

Cancer Genet Cytogenet. 2008 May;183(1):64-8. doi: 10.1016/j.cancergencyto.2008.01.022.

PMID:
18474300
9.

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.

Ximeri M, Galanopoulos A, Klaus M, Parcharidou A, Giannikou K, Psyllaki M, Symeonidis A, Pappa V, Kartasis Z, Liapi D, Hatzimichael E, Kokoris S, Korkolopoulou P, Sambani C, Pontikoglou C, Papadaki HA; Hellenic MDS Study Group.

Haematologica. 2010 Mar;95(3):406-14. doi: 10.3324/haematol.2009.010876. Epub 2009 Sep 22.

10.

Use of Lenalidomide in 5q-Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis.

Giv MJ, Yoosuff A, Bazargan A.

Chest. 2015 Aug;148(2):e35-e37. doi: 10.1378/chest.14-2529.

PMID:
26238834
11.

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.

Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-Lindberg E, Aul C, Schlegelberger B.

Ann Hematol. 2010 Apr;89(4):365-74. doi: 10.1007/s00277-009-0846-z. Epub 2009 Oct 24.

PMID:
19855965
12.

Role of lenalidomide in the treatment of myelodysplastic syndromes.

Komrokji RS, List AF.

Semin Oncol. 2011 Oct;38(5):648-57. doi: 10.1053/j.seminoncol.2011.04.015. Review.

PMID:
21943671
13.

Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?

Vigna E, Recchia AG, Cuzzola M, Morabito L, Gentile M, Morabito F.

Leuk Lymphoma. 2014 Jun;55(6):1408-9. doi: 10.3109/10428194.2013.834053. Epub 2013 Sep 9. No abstract available.

PMID:
23952245
14.
15.

Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.

Balaian E, Schuster C, Schönefeldt C, Germing U, Haase D, Tuve S, Ordemann R, Ehninger G, Bornhäuser M, Oelschlaegel U, Mohr B, von Bonin M, Platzbecker U, Wermke M.

Ann Hematol. 2016 Oct;95(11):1805-10. doi: 10.1007/s00277-016-2775-y. Epub 2016 Aug 10.

PMID:
27510179
16.

Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.

Boruah PK, Bolesta S, Shetty SM.

Pharmacotherapy. 2011 Sep;31(9):925. doi: 10.1592/phco.31.9.925.

PMID:
21923596
17.

Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.

Cannella L, Latagliata R, Breccia M, Carmosino I, Loglisci G, Volpicelli P, Ferretti A, Santopietro M, Vozella F, Girmenia C, Cuzzola M, Oliva EN, Alimena G.

Ann Hematol. 2012 Feb;91(2):309-10. doi: 10.1007/s00277-011-1263-7. Epub 2011 May 28. No abstract available.

PMID:
21625998
18.

Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.

Ziarkiewicz M, Dwilewicz-Trojaczek J, Pastwińska A, Chmarzyńska E, Paszkowska-Kowalewska M, Koperski Ł, Jędrzejczak WW, Ziarkiewicz-Wróblewska B.

Pol J Pathol. 2010;61(2):105-9.

19.

[Molecular mechanisms of lenalidomide for the treatment of myelodysplastic syndromes].

Katayama Y.

Rinsho Ketsueki. 2011 Jul;52(7):447-51. Review. Japanese. No abstract available.

PMID:
21821975
20.

[Mast cell leukemia evolved from RAEB-T (5q-syndrome) in a 12 year-old girl].

Sugita K, Kaneko T, Sekine Y, Taguchi N, Miyauchi J.

Rinsho Ketsueki. 1996 May;37(5):430-6. Japanese.

PMID:
8691590

Supplemental Content

Support Center